ASTRAZENECA PLC

Drug pipeline (253)

Asset	Stage	Revenue	Trials	Status
AIRSUPRA	approved	—	75	approved
ANDEXXA	approved	—	0	—
AQUASOL A	approved	—	0	—
ARIMIDEX	approved	—	32	approved
BAXFENDY	approved	—	23	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (2931)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00673205	phase3	completed	1995-09-01	2008-08-01	AstraZeneca	(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
NCT00997945	phase1	completed	2009-10-01	2010-09-01	AstraZeneca	10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies
NCT00525824	phase3	completed	2007-08-01	2008-09-01	AstraZeneca	12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
NCT00813306	phase1_2	completed	2008-12-01	—	AstraZeneca	14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations
NCT00766415	phase2	completed	2008-11-01	—	AstraZeneca	14729-D9831C00002- 1 Month Biopsy Study

FDA applications (111)

Application

Approved

Type

Applicant

Products

NDA 219878

2026-05-15

NDA

ASTRAZENECA AB

BLA 761451

2026-04-24

BLA

ASTRAZENECA AB

NDA 219943

2025-09-10

NDA

ASTRAZENECA PHARMACEUTICALS LP

NDA 217388

2023-12-21

NDA

ASTRAZENECA AB

NDA 218197

2023-11-16

NDA

ASTRAZENECA PHARMACEUTICALS LP